Samuel Weeks

Samuel Weeks

Auto-generated profile, based on publicly available information

Samuel Weeks

Department of Internal Medicine, University of Rochester Medical Center, Rochester, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in iScience
Verified
Journal Article
Open access
MMMahinbanu Mammadli
Mahinbanu Mammadli
WHWeishan Huang
Weishan Huang
RHRebecca Harris
Rebecca Harris
HXHui Xiong
Hui Xiong
SWSamuel Weeks
Samuel Weeks
MKMobin Karimi
Mobin Karimi
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for hematological malignancies, due to graft-versus-leukemia (GVL) activity mediated by alloreactive donor T cells. However, graft-versus-host disease (GVHD) is also mediated by these cells. Here, we assessed the effect of attenuating TCR-mediated SLP76:ITK interaction in GVL vs. GVHD effects after allo-HSCT. CD8+ and CD4+ donor T cells from mice expressing a Y145F mutation in SLP-76 did not cause GVHD but preserved GVL effects against B-ALL cells. SLP76Y145FKI CD8+ and CD4+ donor T cells also showed less inflammatory cytokine production and migration to GVHD target organs. We developed a novel peptide to specifically inhibit SLP76:ITK interactions, resulting in decreased phosphorylation of PLCγ1 and ERK, decreased cytokine production in human T cells, and separation of GVHD from GVL effects. Altogether, our data suggest that inhibiting SLP76:ITK interaction could be a therapeutic strategy to separate GVHD from GVL effects after allo-HSCT treatment.

1 June 2024 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
KRKelly A. Russo
Kelly A. Russo
SWSamuel Weeks
Samuel Weeks
JKJustin Komisarof
Justin Komisarof
DZDongwei Zhang
Dongwei Zhang
DLDavid Levy
David Levy
CFChunkit Fung
Chunkit Fung